Evaluation of Patients Who Applied to Gaziantep University Faculty of Medicine   Hospital Between 2010 -2020 and Received Treatment with a Diagnosis of Chronic Hepatitis B, in Terms of Treatment Efficacy and Side Effects

Kübra Koçak

Makale detayları

Evaluation of Patients Who Applied to Gaziantep University Faculty of Medicine Hospital Between 2010 -2020 and Received Treatment with a Diagnosis of Chronic Hepatitis B, in Terms of Treatment Efficacy and Side Effects

Yazarlar:

Kübra Koçak

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Kurumları Yönetimi | Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.19 Issue 2, pp.59-64

Belge Tipi:

Makale

Yayın Tarihi:

7/2024

Belge Dili:

Türkçe

Document ID (Org No.):

2001322853

pISSN:

1303-6610

Anahtar kelimeler:

Özet:

 Objective: Chronic hepatitis B infection is one of the important health problems in our country as well as all over the world. In our retrospective study, we aimed to investigate the treatment responses of patients who applied to our hospital between 2010-2020 and received treatment for chronic hepatitis B infection in terms of virological, serological, biochemical. Material-Method: Our study included 412 patients who were followed up with the diagnosis of chronic hepatitis B. Gender, age, biopsy results, type of antiviral treatment administered, laboratory results before treatment and at the 6th, 12th and 24th months of treatment were recorded via the hospital automation system.. Results: Total of the 412 patients, 236 57.28 were male, 176 42.72 were female, and the mean age of the patients was 44.0412.49. The mean fibrosis score of the patients was 2.680.93, and the mean histological activity index HAI was 5.092.16. It was found that 316 77.1 patients were negative for HBeAg and 94 22.9 patients were positive before treatment. Viral suppression was significantly greater in the early tedofovir diproxil fumarate TDF group. In addition, the creatinine levels of the patients who received tenofovir treatment were found to be significantly higher at the 12th and 24th months compared to the Entecavir ETV group. When the patients were compared regarding creatinine change, no difference was detected between the two groups at the 6th month, while a significant increase was observed in the TDF group compared to the ETV group at the 12th and 24th months 12th and 24th months, respectively; p0.001, p0.001. Conclusion: As a result, while TDF treatment is the most effective treatment in patients with rapid virology response, alternative treatments should be preferred as much as possible in patients with impaired renal function.

 Objective: Chronic hepatitis B infection is one of the important health problems in our country as well as all over the world. In our retrospective study, we aimed to investigate the treatment responses of patients who applied to our hospital between 2010-2020 and received treatment for chronic hepatitis B infection in terms of virological, serological, biochemical. Material-Method: Our study included 412 patients who were followed up with the diagnosis of chronic hepatitis B. Gender, age, biopsy results, type of antiviral treatment administered, laboratory results before treatment and at the 6th, 12th and 24th months of treatment were recorded via the hospital automation system.. Results: Total of the 412 patients, 236 57.28 were male, 176 42.72 were female, and the mean age of the patients was 44.0412.49. The mean fibrosis score of the patients was 2.680.93, and the mean histological activity index HAI was 5.092.16. It was found that 316 77.1 patients were negative for HBeAg and 94 22.9 patients were positive before treatment. Viral suppression was significantly greater in the early tedofovir diproxil fumarate TDF group. In addition, the creatinine levels of the patients who received tenofovir treatment were found to be significantly higher at the 12th and 24th months compared to the Entecavir ETV group. When the patients were compared regarding creatinine change, no difference was detected between the two groups at the 6th month, while a significant increase was observed in the TDF group compared to the ETV group at the 12th and 24th months 12th and 24th months, respectively; p0.001, p0.001. Conclusion: As a result, while TDF treatment is the most effective treatment in patients with rapid virology response, alternative treatments should be preferred as much as possible in patients with impaired renal function.

 Objective: Chronic hepatitis B infection is one of the important health problems in our country as well as all over the world. In our retrospective study, we aimed to investigate the treatment responses of patients who applied to our hospital between 2010-2020 and received treatment for chronic hepatitis B infection in terms of virological, serological, biochemical. Material-Method: Our study included 412 patients who were followed up with the diagnosis of chronic hepatitis B. Gender, age, biopsy results, type of antiviral treatment administered, laboratory results before treatment and at the 6th, 12th and 24th months of treatment were recorded via the hospital automation system.. Results: Total of the 412 patients, 236 57.28 were male, 176 42.72 were female, and the mean age of the patients was 44.0412.49. The mean fibrosis score of the patients was 2.680.93, and the mean histological activity index HAI was 5.092.16. It was found that 316 77.1 patients were negative for HBeAg and 94 22.9 patients were positive before treatment. Viral suppression was significantly greater in the early tedofovir diproxil fumarate TDF group. In addition, the creatinine levels of the patients who received tenofovir treatment were found to be significantly higher at the 12th and 24th months compared to the Entecavir ETV group. When the patients were compared regarding creatinine change, no difference was detected between the two groups at the 6th month, while a significant increase was observed in the TDF group compared to the ETV group at the 12th and 24th months 12th and 24th months, respectively; p0.001, p0.001. Conclusion: As a result, while TDF treatment is the most effective treatment in patients with rapid virology response, alternative treatments should be preferred as much as possible in patients with impaired renal function.

 Amaç: Kronik hepatit B enfeksiyonu tüm dünyada olduğu gibi ülkemizde de önemli sağlık problemlerinden biridir. Çalışmamızda hastanemize 2010-2020 yılları arasında başvuran ve kronik hepatit B enfeksiyonu nedeniyle tedavi alan hastaların tedavi yanıtlarını virolojik, serolojik, biyokimyasal tedavi yanıtlarını araştırmayı amaçladık. Materyal-Metot: Çalışmamıza kronik hepatit B tanısı ile takip edilen 412 hasta dahil edildi. Hastaların cinsiyet, yaş, karaciğer biyopsisinde fibrozis ve histolojik aktivite indeksi HAİ sonuçları, uygulanan antiviral tedavi türü, tedavi öncesi ve tedavinin 6. 12. ve 24. aylarındaki laboratuvar sonuçları hastane otomasyon sistemi üzerinden kaydedildi. Bulgular: Toplam 412 hastanın 236sı erkek 57,28, 176 sının kadın 42,72 olduğu tespit edildi ve hastaların yaş ortalaması 44,0412,49 idi. Ortalama fibrozis skoru 2,680,93, ortalama HAİ 5,092,16 olarak tespit edildi. Tedavi öncesi 316 77,1 hastada HBeAg negatif, 94 22,9 hastada ise pozitif saptandı. HBeAg pozitif ve negatif hastalar karşılaştırıldığında HBV DNA, ALT, AST değerleri ve HAİ skorları HBeAg pozitif hastalarda anlamlı olarak yüksek saptandı. AFP ve INR değerleri ile fibrozis skorları arasında anlamlı bir fark yoktu. Tenofovir disoproksil fumarat TDF ve Entecavir ETV etkinlik ve yan etki bakımından karşılaştırıldığında; viral süpresyon, erken dönemde TDF grubunda anlamlı olarak daha fazlaydı. ALT normalizasyonu ise 6. ve 12. aylarda ETV grubunda anlamlı olarak daha fazla iken, 24. ayda her iki grup arasında anlamlı bir fark yoktu. Hastalar kreatinin değişimi konusunda karşılaştırıldığında ise 6. ayda her iki grup arasında bir fark saptanmazken, 12. ve 24. aylarda TDF grubunda ETV grubuna göre anlamlı bir artış görülmüştür 12. ve 24. Aylar sırasıyla; p0,001, p0,001. Sonuç: Sonuç olarak hızlı virolojik yanıt istenen hastalarda TDF tedavisi en etkin tedavi olarak dikkat çekmekteyken, böbrek fonksiyonları bozuk olan hastalarda ise mümkün olduğu kadar alternatif tedavilerin tercih edilmesi gerekmektedir.

Makale detayları

Evaluation of Patients Who Applied to Gaziantep University Faculty of Medicine Hospital Between 2010 -2020 and Received Treatment with a Diagnosis of Chronic Hepatitis B, in Terms of Treatment Efficacy and Side Effects

Yazarlar:

Kübra Koçak

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Kurumları Yönetimi | Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.19 Issue 2, pp.59-64

Belge Tipi:

Makale

Yayın Tarihi:

7/2024

Belge Dili:

Türkçe

Document ID (Org No.):

2001322853

pISSN:

1303-6610

ALT

Chronic Hepatitis B

Entecavir

HBeAg

Tenofovir Disoproxil Fumarate

treatmentALT

Entekavir

HBeAg

Kronik Hepatit B

Tenofovir Disoproksil Fumarat

tedavi

Sayı

Makale detayları

Yazarlar: Kübra Koçak

Yayıncı: Kahramanmaras Sutcu Imam University

Ana Başlıklar: Sağlık Kurumları Yönetimi | Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi: Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.19 Issue 2, pp.59-64

Belge Tipi: Makale

Yayın Tarihi: 7/2024

Belge Dili: Türkçe

Document ID (Org No.): 2001322853

pISSN: 1303-6610

Sayı

Yazarlar:

Kübra Koçak

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Kurumları Yönetimi | Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.19 Issue 2, pp.59-64

Belge Tipi:

Makale

Yayın Tarihi:

7/2024

Belge Dili:

Türkçe

Document ID (Org No.):

2001322853

pISSN:

1303-6610